Ornidazole + Fluconazole + Azithromycin KitThird Party Manufacturing in India

The Ornidazole + Fluconazole + Azithromycin Kit combines three distinct mechanisms of action to provide comprehensive coverage against mixed urogenital and sexually transmitted infections. Ornidazole, a nitroimidazole derivative, works by penetrating bacterial and protozoal cells and undergoing reduction by nitroreductase enzymes. The reduced form causes DNA strand breakage and inhibits nucleic acid synthesis, effectively targeting anaerobic bacteria and protozoa including Trichomonas vaginalis and Gardnerella vaginalis. Fluconazole, a triazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis in the fungal cell membrane. This compromises membrane integrity and prevents fungal replication, providing coverage against Candida species commonly involved in vulvovaginal infections. Azithromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting mRNA translation and protein synthesis. It provides broad-spectrum coverage against atypical pathogens including Chlamydia trachomatis and Neisseria gonorrhoeae. This triple-action kit ensures simultaneous treatment of mixed infections involving protozoa, fungi, and bacteria in a single therapeutic course.

Therapeutic Uses

The Ornidazole + Fluconazole + Azithromycin Kit is prescribed for the treatment of:

• Mixed Urogenital Infections: Comprehensive treatment of polymicrobial infections involving Trichomonas vaginalis, Candida species, and Chlamydia trachomatis.
• Sexually Transmitted Infections: Empiric therapy for symptomatic STIs where co-infection with multiple pathogens is suspected or confirmed.
• Vaginal Discharge Syndrome: Treatment of abnormal vaginal discharge caused by mixed bacterial, fungal, and protozoal aetiologies.
• Pelvic Inflammatory Disease: As part of a combination regimen covering the major pathogens implicated in PID.

Why Manufacturers Choose This Kit

Combination kits for STI management represent a growing segment in the Indian pharmaceutical market, driven by high disease burden and the clinical need for convenient, comprehensive therapy. The Ornidazole + Fluconazole + Azithromycin combination covers the three most common pathogens responsible for urogenital infections — Trichomonas, Candida, and Chlamydia — making it a preferred choice for empiric treatment. Indian contract manufacturers benefit from well-established API supply chains for all three active ingredients and straightforward formulation processes. The kit format allows for premium pricing compared to individual tablets, improving margins for PCD franchise partners and distributors.

This makes this kit one of the most sought-after products for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.